NASDAQ$AURA
Aura Biosciences Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Aura Biosciences reported financial results and clinical development for the third quarter of 2022.
Aura Biosciences reported a net loss of $15.9 million for the third quarter of 2022. The company's cash and cash equivalents totaled $111.5 million as of September 30, 2022, which is expected to fund operations into 2024. The company finalized the global Phase 3 design in alignment with regulatory agencies and selected suprachoroidal route of administration to evaluate the efficacy and safety of bel-sar in early-stage CM. Aura dosed the first patient in a Phase 1 clinical trial of bel-sar for the treatment of non-muscle invasive bladder cancer (NMIBC).
- Global Phase 3 trial design with suprachoroidal route of administration of Belzupacap Sarotalocan in early-stage choroidal melanoma was announced.
- The first patient was dosed in the Phase 1 study evaluating Belzupacap Sarotalocan for the treatment of non-muscle invasive bladder cancer.
- Positive interim Phase 2 data evaluating SC administration of bel-sar for the first-line treatment of patients with early-stage CM were presented at AAO 2022, showing a statistically significant reduction in the tumor growth rate.
- Aura plans to file an IND for choroidal metastasis with the FDA in Q4 of 2022.
Headline financials
Revenue & EPS history
Aura Biosciences · Revenue · Quarterly
$600K
Forward guidance
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws.
Tailwinds
- therapeutic potential of bel-sar for the treatment of cancers including choroidal melanoma, non-muscle invasive bladder cancer and choroidal metastases
- expectations for the Phase 2 and Phase 3 clinical trials of bel-sar for early-stage choroidal melanoma
- expectations regarding the estimated patient populations and related market opportunities for bel-sar
- improved quality of life of patients after treatment with bel-sar
- potential paradigm shift in the approach to the treatment of choroidal melanoma
Headwinds
- uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials
- the risk that the results of Aura’s clinical trials may not be predictive of future results in connection with future clinical trials
- the risk that interim data from ongoing clinical trials may not be predictive of final data from completed clinical trials
- whether Aura will receive regulatory approvals to conduct trials or to market products
- whether Aura’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q3 2022
+1.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-7.0%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+26.0%
Q3 2021
Best reaction
-8.9%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.1% | -5.5% | -24.3% | |
| Q3 2025 | -0.7% | -2.9% | +17.4% | |
| Q2 2025 | +4.2% | -3.6% | -11.0% | |
| Q1 2025 | +1.9% | -0.5% | +6.8% | |
| Q4 2024 | -6.7% | -15.5% | -23.2% | |
| Q3 2024 | -7.3% | -15.0% | -24.2% | |
| Q1 2024 | -1.1% | +1.9% | +1.6% | |
| Q4 2023 | +2.9% | +1.7% | -5.4% | |
| Q3 2023 | +4.5% | +8.6% | +18.9% | |
| Q2 2023 | -8.9% | -8.8% | -16.4% | |
| Q1 2023 | +0.5% | +7.3% | +22.4% | |
| Q4 2022 | -1.0% | -1.0% | -15.6% | |
| Q3 2022 | +10.1% | +16.4% | +4.4% | |
| Q2 2022 | -0.5% | -2.6% | -19.0% | |
| Q1 2022 | +4.9% | +8.1% | -4.5% | |
| Q2 2021 | -1.5% | +8.7% | -21.4% | |
| Q4 2021 | -1.5% | +8.7% | -21.4% | |
| Q3 2021 | +26.0% | -1.1% | -10.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro